Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Abandoned Power Plant a $38 Billion Warning Sign for India Banks - Bloomberg

2018-06-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PNJZY 532461 532627 JPPOWER PNB LITL 532778 SBAZ

0
Orient Cement shares jump nearly 7% on deal call-off

2018-05-31 moneycontrol
Shares of Orient Cement surged nearly 7 percent after the company announced the termination of the agreement to acquire two entities from Jaypee group firms. The stock surged 6.57 percent to end at Rs 129 on BSE. Intra-day, it jumped 15.24 percent to Rs 139.50.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

0
Jaiprakash Power Ventures Limited - Updates

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

0
Orient Cement stock jumps 15% after deal to buy 2 units from Jaypee called off

2018-05-31 moneycontrol
Orient Cement share price rallied more than 15 percent intraday Thursday after the company called off a deal to acquire 2 units from Jaypee. Jaiprakash Associates lost 3 percent.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

41
Market Live: Sensex up 150 pts, Midcap underperforms; Tech Mahindra, ONGC jump

2018-05-31 moneycontrol
Indian Oil Corporation, which has for decades been India's biggest company by turnover, last week posted a record net profit of Rs 21,346 crore in the fiscal year ended March 31, 2018 (FY 2017-18), up 12 per cent from Rs 19,106 crore in the last fiscal.
IOC 500325 JIPKY BHUSANSTL TCHQY 532755 532754 535754 UCLQY 500570 CLNDY 500055 RLNIY 500413 AXB EVSJF 532627 530965 ULTRACEMCO TECHM 500182 AXBA 500180 520051 TCS COALINDIA RELIANCE PUNJLLOYD GMQRY GMRINFRA 532538 TTNQY 533278 532215 THOMASCOOK 532540 AXISBANK RIGD HDFCBANK HEROMOTOCO TATAMOTORS ORIENTCEM ESI IBN UCLQF JPASSOCIAT 539207 AXBKY 532532 ICICIBANK 532693 HDB 532174 JAMNAAUTO JPPOWER HRTQY MANPASAND TTM

0
Orient Cement calls off deal to acquire 2 units from Jaypee

2018-05-31 moneycontrol
CK Birla Group firm Orient Cement has terminated the agreement to acquire two entities, Bhilai Jaypee Cement and Nigrie Cement Grinding Unit, from Jaypee group firms for a total consideration of Rs 1,946 crore.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

0
Jaiprakash Power Ventures Q4 loss at Rs157.62 crore

2018-05-05 livemint
New Delhi: Jaiprakash Power Ventures on Saturday reported a net loss of Rs157.62 crore for the fourth quarter ended 31 March 2018. The company had posted a net loss of Rs 229.39 crore in the same period of the previous fiscal.
532627 JPPOWER

0
Jaiprakash Power Ventures Limited - Financial Result Updates

2018-05-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

0
JSW Energy mulls taking Jaiprakash Power to NCLT

2018-05-04 freepressjournal.in
Mumbai : Sajjan Jindal-led JSW Energy is considering initiating Insolvency and Bankruptcy Code (IBC) resolution process against Jaiprakash Power Ventures (JPVL). At present, the company and lenders are discussing with JPVL to find a solution and speed up the recovery process.
532627 JPPOWER JSWENERGY 533148

0
JSW Energy reports Rs480 crore loss in March quarter

2018-05-03 livemint
Mumbai: JSW Energy on Thursday reported consolidated net loss of Rs480.05 crore in the January-March quarter of this fiscal, compared to a net profit of Rs24.76 crore in the year-ago period.
532627 JPPOWER JSWENERGY 533148

8
ICICI case: BBB member’s Avista stint under scanner

2018-04-17 freepressjournal.in
New Delhi : The finance ministry is looking at the professional assistance provided by newly-appointed Banks Board Bureau (BBB) member P Pradeep Kumar during his stint at Avista Advisory Group, which is caught in the controversy involving ICICI Bank and Videocon Group, sources said.
JIPKY IBN 532627 532505 JPASSOCIAT 530323 532775 GTLINFRA 532532 ICICIBANK 532174 ERAINFRA JPPOWER UCOBANK SBAZ

0
Jaiprakash Power Ventures Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532627 JPPOWER

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...